Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1983 Jan;49(1):65–76. doi: 10.1136/hrt.49.1.65

Effects of captopril in acute and chronic heart failure. Correlations with plasma levels of noradrenaline, renin, and aldosterone.

G J Wenting, A J Man in't veld, A J Woittiez, F Boomsma, K Laird-Meeter, M L Simoons, P G Hugenholtz, M A Schalekamp
PMCID: PMC485212  PMID: 6336940

Abstract

The angiotensin-converting enzyme inhibitor, captopril, was given to 19 patients with severe heart failure. Seven patients had acute myocardial infarction and the remainder had chronic myocardial damage caused by ischaemia or valvular disease. Cardiac filling pressures were raised in all, the pulmonary capillary "wedge" pressure being 17 mmHg or more. Captopril, 50 mg orally, raised stroke volume and cardiac output, and reduced heart rate, cardiac filling pressures, systemic arterial pressure, and the plasma concentrations of aldosterone and noradrenaline. These changes were attended by clinical improvement. Decrements in cardiac filling pressures, systemic arterial pressure, and total peripheral resistance were positively correlated with pretreatment plasma renin. Long-term treatment with captopril was offered to 14 patients. Four patients with severe coronary disease died suddenly after initial clinical improvement. In nine patients haemodynamic measurements were repeated after three months. The results showed sustained effects on cardiac output and filling pressures but there was no loss of body weight. The haemodynamic effects were at least as good as with previous vasodilators. The fall in systemic arterial pressure, however, was greater with captopril. Captopril may become a valuable adjunct to the treatment of acute and chronic heart failure, but more information about its effect on coronary blood flow is required.

Full text

PDF
66

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold S. B., Williams R. L., Ports T. A., Baughman R. A., Benet L. Z., Parmley W. W., Chatterjee K. Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med. 1979 Sep;91(3):345–349. doi: 10.7326/0003-4819-91-3-345. [DOI] [PubMed] [Google Scholar]
  2. Atlas S. A., Case D. B., Sealey J. E., Laragh J. H., McKinstry D. N. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis. Hypertension. 1979 May-Jun;1(3):274–280. doi: 10.1161/01.hyp.1.3.274. [DOI] [PubMed] [Google Scholar]
  3. Awan N. A., Miller R. R., Miller M. P., Specht K., Vera Z., Mason D. T. Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output. Am J Med. 1978 Jul;65(1):146–154. doi: 10.1016/0002-9343(78)90703-9. [DOI] [PubMed] [Google Scholar]
  4. Brown J. J., Davies D. L., Johnson V. W., Lever A. F., Robertson J. I. Renin relationships in congestive cardiac failure, treated and untreated. Am Heart J. 1970 Sep;80(3):329–342. doi: 10.1016/0002-8703(70)90098-0. [DOI] [PubMed] [Google Scholar]
  5. Chatterjee K., Parmley W. W. The role of vasodilator therapy in heart failure. Prog Cardiovasc Dis. 1977 Jan-Feb;19(4):301–325. doi: 10.1016/0033-0620(77)90006-8. [DOI] [PubMed] [Google Scholar]
  6. Cody R. J., Jr, Tarazi R. C., Bravo E. L., Fouad F. M. Haemodynamics of orally-active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clin Sci Mol Med. 1978 Nov;55(5):453–459. doi: 10.1042/cs0550453. [DOI] [PubMed] [Google Scholar]
  7. Cohn J. N., Franciosa J. A. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977 Jul 7;297(1):27–31. doi: 10.1056/NEJM197707072970105. [DOI] [PubMed] [Google Scholar]
  8. Creager M. A., Halperin J. L., Bernard D. B., Faxon D. P., Melidossian C. D., Gavras H., Ryan T. J. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981 Sep;64(3):483–489. doi: 10.1161/01.cir.64.3.483. [DOI] [PubMed] [Google Scholar]
  9. Curtiss C., Cohn J. N., Vrobel T., Franciosa J. A. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978 Nov;58(5):763–770. doi: 10.1161/01.cir.58.5.763. [DOI] [PubMed] [Google Scholar]
  10. Demoulin J. C., Bertholet M., Soumagne D., David J. L., Kulbertus H. E. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet. 1981 May 30;1(8231):1186–1188. doi: 10.1016/s0140-6736(81)92352-7. [DOI] [PubMed] [Google Scholar]
  11. Derkx F. H., von Gool J. M., Wenting G. J., Verhoeven R. P., Man in 't Veld A. J., Schalekamp M. A. Inactive renin in human plasma. Lancet. 1976 Sep 4;1(7984):496–499. doi: 10.1016/s0140-6736(76)90791-1. [DOI] [PubMed] [Google Scholar]
  12. Dzau V. J., Colucci W. S., Hollenberg N. K., Williams G. H. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation. 1981 Mar;63(3):645–651. doi: 10.1161/01.cir.63.3.645. [DOI] [PubMed] [Google Scholar]
  13. Faxon D. P., Halperin J. L., Creager M. A., Gavras H., Schick E. C., Ryan T. J. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May;101(5):548–556. doi: 10.1016/0002-8703(81)90220-9. [DOI] [PubMed] [Google Scholar]
  14. Fraser R., Guest S., Young J. A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man. Clin Sci Mol Med. 1973 Sep;45(3):411–415. doi: 10.1042/cs0450411. [DOI] [PubMed] [Google Scholar]
  15. Hatton R., Clough D., Faulkner K., Conway J. Angiotensin-converting enzyme inhibitor resets baroreceptor reflexes in conscious dogs. Hypertension. 1981 Nov-Dec;3(6):676–681. doi: 10.1161/01.hyp.3.6.676. [DOI] [PubMed] [Google Scholar]
  16. Henry D. P., Starman B. J., Johnson D. G., Williams R. H. A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci. 1975 Feb 1;16(3):375–384. doi: 10.1016/0024-3205(75)90258-1. [DOI] [PubMed] [Google Scholar]
  17. LeJemtel T. H., Elkayam U., Ribner H. S., Hellman C., Strom J., Frishman W., Strobeck J., Sonnenblick E. H. Variable hemodynamic response to oral hydralazine in patients with refractory congestive heart failure. Eur Heart J. 1980 Jun;1(3):157–163. doi: 10.1093/oxfordjournals.eurheartj.a061114. [DOI] [PubMed] [Google Scholar]
  18. Levine T. B., Franciosa J. A., Cohn J. N. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation. 1980 Jul;62(1):35–41. doi: 10.1161/01.cir.62.1.35. [DOI] [PubMed] [Google Scholar]
  19. MacGregor G. A., Markandu N. D., Roulston J. E., Jones J. C., Morton J. J. Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature. 1981 May 28;291(5813):329–331. doi: 10.1038/291329a0. [DOI] [PubMed] [Google Scholar]
  20. Majid P. A., Sharma B., Taylor S. H. Phentolamine for vasodilator treatment of severe heart-failure. Lancet. 1971 Oct 2;2(7727):719–724. doi: 10.1016/s0140-6736(71)92098-8. [DOI] [PubMed] [Google Scholar]
  21. Maslowski A. H., Ikram H., Nicholls M. G., Espiner E. A. Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure. Lancet. 1981 Jan 10;1(8211):71–74. doi: 10.1016/s0140-6736(81)90004-0. [DOI] [PubMed] [Google Scholar]
  22. Mason D. T. Symposium on vasodilator and inotropic therapy of heart failure. Symposium perspective. Am J Med. 1978 Jul;65(1):101–105. doi: 10.1016/0002-9343(78)90699-x. [DOI] [PubMed] [Google Scholar]
  23. Packer M., Meller J., Gorlin R., Herman M. V. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979 Mar;59(3):531–539. doi: 10.1161/01.cir.59.3.531. [DOI] [PubMed] [Google Scholar]
  24. Packer M., Meller J. Oral vasodilator therapy for chronic heart failure: a plea for caution. Am J Cardiol. 1978 Oct;42(4):686–689. doi: 10.1016/0002-9149(78)90642-2. [DOI] [PubMed] [Google Scholar]
  25. Sharpe D. N., Douglas J. E., Coxon R. J., Long B. Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet. 1980 Nov 29;2(8205):1154–1157. doi: 10.1016/s0140-6736(80)92593-3. [DOI] [PubMed] [Google Scholar]
  26. Stein L., Henry D. P., Weinberger M. H. Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. Am J Med. 1981 Apr;70(4):825–832. doi: 10.1016/0002-9343(81)90539-8. [DOI] [PubMed] [Google Scholar]
  27. Tarazi R. C., Fouad F. M., Ceimo J. K., Bravo E. L. Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure. Am J Cardiol. 1979 Oct 22;44(5):1013–1018. doi: 10.1016/0002-9149(79)90237-6. [DOI] [PubMed] [Google Scholar]
  28. Turini G. A., Brunner H. R., Gribic M., Waeber B., Gavras H. Improvement of chronic congestive heart-failure by oral captopril. Lancet. 1979 Jun 9;1(8128):1213–1215. doi: 10.1016/s0140-6736(79)91897-x. [DOI] [PubMed] [Google Scholar]
  29. Walsh W. F., Greenberg B. H. Results of long-term vasodilator therapy in patients with refractory congestive heart failure. Circulation. 1981 Sep;64(3):499–505. doi: 10.1161/01.cir.64.3.499. [DOI] [PubMed] [Google Scholar]
  30. Zelis R., Flaim S. F., Moskowitz R. M., Nellis S. H. How much can we expect from vasodilator therapy in congestive heart failure? Circulation. 1979 Jun;59(6):1092–1097. doi: 10.1161/01.cir.59.6.1092. [DOI] [PubMed] [Google Scholar]
  31. de Bruyn J. H., Man in't Veld A. J., Wenting G. J., Derkx F. H., Schalekamp M. A. Haemodynamic profile of captopril treatment in various forms of hypertension. Eur J Clin Pharmacol. 1981;20(3):163–168. doi: 10.1007/BF00544593. [DOI] [PubMed] [Google Scholar]
  32. ten Cate F. J., Hugenholtz P. G., Roelandt J. Ultrasound study of dynamic behaviour of left ventricle in genetic asymmetric septal hypertrophy. Br Heart J. 1977 Jun;39(6):627–633. doi: 10.1136/hrt.39.6.627. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES